Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, Zhejiang, China (mainland).
Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China (mainland).
Med Sci Monit. 2018 Jul 13;24:4841-4850. doi: 10.12659/MSM.910608.
BACKGROUND Alteration of DNA methylation of tumor suppressor genes (TSGs) is one of the most consistent epigenetic changes in human cancers. DNMTs play several important roles in DNA methylation and development of cancers. Regarding DNMTs protein expressions, little is known about the clinical significance and correlation with promoter methylation status of TSGs in human pituitary adenomas. MATERIAL AND METHODS We analyzed the protein expression of 3 DNMTs using immunohistochemistry and assessed DNA hypermethylation of RASSF1A, CDH13, CDH1, and CDKN2A (p16) in 63 pituitary adenomas. We examined associations between DNMTs expression and clinicopathological features or promoter methylation status of TSGs. RESULTS Overexpression of DNMTs was detected in pituitary adenomas. Frequencies of DNMT1 overexpression were significantly higher in macroadenomas, invasive tumors, and grade III and IV tumors. DNMT3A was frequently detected in invasive tumors and grade IV tumors. In addition, DNMT1 and DNMT3A were frequently detected in high-methylation tumors. Furthermore, in multivariate logistic regression, the significant association between DNMT1 or DNMT3A and high-methylation status persisted after adjusting for clinicopathological features. CONCLUSIONS Our findings suggested that tumor overexpression of DNMT1 and DNMT3A is associated with tumor aggressive behavior and high-methylation status in pituitary adenomas. Our data support a possible role of DNMT1 and DNMT3A in TSG promoter methylation leading to pituitary adenoma invasion and suggest that inhibition of DNMTs has the potential to become a new therapeutic approach for invasive pituitary adenoma.
肿瘤抑制基因(TSGs)的 DNA 甲基化改变是人类癌症中最一致的表观遗传变化之一。DNMTs 在 DNA 甲基化和癌症发展中发挥着重要作用。关于 DNMTs 蛋白表达,人们对人类垂体腺瘤中 TSGs 的启动子甲基化状态与 DNMTs 蛋白表达的临床意义和相关性知之甚少。
我们使用免疫组织化学分析了 3 种 DNMTs 的蛋白表达,并评估了 63 例垂体腺瘤中 RASSF1A、CDH13、CDH1 和 CDKN2A(p16)的 DNA 高甲基化状态。我们研究了 DNMTs 表达与临床病理特征或 TSGs 启动子甲基化状态之间的关系。
在垂体腺瘤中检测到 DNMTs 的过表达。DNMT1 过表达的频率在大腺瘤、侵袭性肿瘤和 3 级和 4 级肿瘤中显著更高。DNMT3A 在侵袭性肿瘤和 4 级肿瘤中频繁检测到。此外,DNMT1 和 DNMT3A 在高甲基化肿瘤中频繁检测到。此外,在多变量逻辑回归中,在调整临床病理特征后,DNMT1 或 DNMT3A 与高甲基化状态之间的显著相关性仍然存在。
我们的研究结果表明,DNMT1 和 DNMT3A 在垂体腺瘤中的肿瘤过表达与肿瘤侵袭行为和高甲基化状态有关。我们的数据支持 DNMT1 和 DNMT3A 在 TSG 启动子甲基化中的可能作用,导致垂体腺瘤的侵袭,并表明抑制 DNMTs 有可能成为侵袭性垂体腺瘤的一种新的治疗方法。